The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screening of potential protein and small molecule therapeutics. (2) To develop an insulin stimulated glucose uptake assay in differentiated 3T3-L1 adipocytes using fluorescent 2-deoxy glucose (2-DOG) analog. (3) To integrate and perform a functional 2-DOG uptake assay in the microfluidics based multi-well cell culture biochip. The deliverable from this completed project is a cost-effective microfluidics based platform suitable for high throughput screening of proteins and small molecule therapeutic compounds.
Public Health Relevance: The long term objective of the project is to identify protein and small molecule therapeutics to treat diseases such as diabetes, obesity, cancer and neurological disorders. As a first step towards this objective, a platform based on microfluidics technology and functional cell bioassays is being developed to screen the entire human proteome and small molecule libraries in a cost-effective and time saving manner. Presently, safety and efficacy of most of the drugs in the market is still a primary concern. However, with more therapies becoming available, it is possible that not only safety standards will be met but also the cost of drugs will be lowered.
Thesaurus Terms: Adipocytes;Adipose Cell;Adipose Tissue;Assay;Bioassay;Biologic Assays;Biological Assay;Blood Plasma;Cancers;Cell Culture System;Cell Culture Techniques;Cell Survival;Cell Viability;Cells;Chemicals;D-Glucose;Development;Devices;Dextrose;Diabetes Mellitus;Diagnostic;Dimensions;Disease;Disorder;Dose;Drug Costs;Drugs;Fat Cells;Fatty Tissue;Fluorescence;Gene Transcription;Generalized Growth;Genetic Transcription;Glass;Glucose;Goals;Growth;H3 Radionuclide;High Throughput Assay;Human;Human Resources;Humulin R;Image;Insulin;Insulin (Ox), 8a-L-Threonine-10a-L-Isoleucine-30b-L-Threonine-;Investigators;Label;Libraries;Lipocytes;Liquid Chromatography;Malignant Neoplasms;Malignant Tumor;Man (Taxonomy);Manpower;Marketing;Mature Lipocyte;Mature Fat Cell;Medication;Methods;Microfluidic;Microfluidics;Microscope;Modern Man;Molecular;Nervous System Diseases;Neurologic Disorders;Neurological Disorders;Novolin R;Obesity;Patients;Pharmaceutic Preparations;Pharmaceutical Preparations;Plasma;Plasma Serum;Proteins;Proteome;Rna Expression;Radioactive;Radiolabeled;Reagent;Regular Insulin;Research Personnel;Researchers;Reticuloendothelial System, Serum, Plasma;Risk;Robotics;Safety;Screening Procedure;Slide;Technology;Testing;Therapeutic;Time;Tissue Growth;Transcription;Tritium;Tube;Vial;Vial Device;Adipose;Adiposity;Base;Biochip;Cell Culture;Chemical Library;Corpulence;Corpulency;Corpulentia;Cost;Cost Effective;Cost-Effective;Culture Plates;Design;Designing;Developmental;Diabetes;Diabetes Management;Diabetic Management;Disease/Disorder;Drug/Agent;Gene Product;Glucose Analog;Glucose Uptake;High Throughput Screening;High Throughput Technology;Imaging;Malignancy;Meetings;Neoplasm/Cancer;Nervous System Disorder;Neurological Disease;New Therapeutics;Next Generation Therapeutics;Novel;Novel Therapeutics;Obese;Obese People;Obese Person;Obese Population;Ontogeny;Personnel;Radioactive Hydrogen;Radiolabel;Radiotracer;Response;Screening;Screenings;Small Molecule;Small Molecule Libraries;White Adipose Tissue;Yellow Adipose Tissue
